Abciximab
Also known as: 7E3 Fab, Abciximab, Anti-GPIIb/IIIa antibody fragment, c7E3, c7E3 Fab, ReoPro
Source Abciximab at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Abciximab is a chimeric Fab fragment used intravenously to prevent acute thrombotic complications during percutaneous coronary interventions.
Mechanism of Action
Binds to the platelet glycoprotein IIb/IIIa receptor, blocking fibrinogen attachment and inhibiting platelet aggregation.
Routes of Administration
Goals & Uses
- Adjunct in primary PCI for STEMICardiovascular / Acute Coronary SyndromeModerate
- Prevent periprocedural thrombotic eventsAntiplatelet TherapyHigh
- Adjunct therapy in unstable angina refractory to conventional treatmentCardiovascular / AntiplateletHigh
- Reduce incidence of myocardial infarctionCardiovascularHigh
- Prevent periprocedural thrombosisAntithromboticHigh
- Reduction of acute myocardial infarction in PCI patientsCardiovascularHigh
- Stent thrombosis preventionCardiovascular / Interventional CardiologyHigh
- Prevention of ischemic complications during PCICardiovascular / AntiplateletHigh
Contraindications
- Oral anticoagulant therapy within 7 days (unless PT ≤1.2× control)Drug Interaction / Bleeding RiskHigh
- History of stroke within 2 years or any stroke with significant residual neurological deficitNeurological / Bleeding RiskHigh
- Known hypersensitivity to murine proteins or abciximabImmunologicalHigh
- Active internal bleedingBleeding RiskHigh
- Recent (≤30 days) ischemic stroke or intracranial hemorrhageNeurologicHigh
- Thrombocytopenia (platelet count < 100,000 cells/μL)HematologicalHigh
- Severe uncontrolled hypertensionCardiovascularModerate
- Recent major surgery or trauma (within 6 weeks)Surgical / Bleeding RiskHigh
- Recent (within 30 days) ischemic strokeNeurologicHigh
Adverse Effects
- Nausea / VomitingGastrointestinalCommon
- Hypersensitivity / anaphylaxisImmunologicalRare
- ThrombocytopeniaHematologicUncommonLow platelet count
- Bleeding (major and minor)HematologicalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- BleedingHematologicCommonAbnormal bleeding or hemorrhage
- Back painMusculoskeletalCommonPain in the back
Drug Interactions
- HeparinHigh
- DextranModerate
- AspirinModerate
- Oral antiplatelet agents (aspirin, clopidogrel)Moderate
- Low molecular weight heparins (LMWH)Moderate
- Thrombolytics (e.g., alteplase, streptokinase)High
- Glycoprotein IIb/IIIa inhibitors (e.g., tirofiban, eptifibatide)High
- Unfractionated HeparinHigh
- Other GPIIb/IIIa inhibitors (e.g., eptifibatide, tirofiban)High
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Prior abciximab exposureImmunologicalRelative
- Pediatric patientsAgeRelative
- Renal impairment (CrCl <30 mL/min)RenalRelative
- Patients with severe hepatic impairmentHepaticRelative
- Elderly patients (≥65 years)Age RelatedRelative
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- European UnionApprovedApproved: Prevention of cardiac ischemic complications during PCIEMA approval; same dosing regimen as US.
- United StatesApprovedApproved: Adjunct to coronary artery bypass grafting, Adjunct to percutaneous coronary interventionFDA approved; administered IV as a bolus followed by infusion.
- United KingdomApprovedApproved: Adjunct to percutaneous coronary interventionAvailable via NHS formularies.
Approved in the US (FDA) and EU for use in coronary artery disease procedures; administered as a short‑infusion.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Abciximab?
Abciximab is a chimeric Fab fragment used intravenously to prevent acute thrombotic complications during percutaneous coronary interventions.
What is Abciximab used for?
Abciximab is educationally associated with: Adjunct in primary PCI for STEMI, Prevent periprocedural thrombotic events, Adjunct therapy in unstable angina refractory to conventional treatment, Reduce incidence of myocardial infarction, Prevent periprocedural thrombosis, Reduction of acute myocardial infarction in PCI patients, Stent thrombosis prevention, Prevention of ischemic complications during PCI. Educational only — not medical advice.
How is Abciximab administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Abciximab?
Reported adverse effects include: Nausea / Vomiting, Hypersensitivity / anaphylaxis, Thrombocytopenia, Bleeding (major and minor), Hypotension, Bleeding, Back pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Abciximab?
Recorded contraindications: Oral anticoagulant therapy within 7 days (unless PT ≤1.2× control), History of stroke within 2 years or any stroke with significant residual neurological deficit, Known hypersensitivity to murine proteins or abciximab, Active internal bleeding, Recent (≤30 days) ischemic stroke or intracranial hemorrhage, Thrombocytopenia (platelet count < 100,000 cells/μL), Severe uncontrolled hypertension, Recent major surgery or trauma (within 6 weeks), Recent (within 30 days) ischemic stroke. Consult a qualified clinician before use.